Message from the Director of Research
Welcome to urologic research at UC Davis
We are proud to be one of the largest urologic research programs in the nation, featuring six dedicated research laboratories. In 2014, we secured more than $4 million in research grants. We have active basic science, translational and clinical research programs in the areas of prostate, bladder, kidney and pediatric urological diseases.
The central theme of urologic cancer research is to improve the treatment outcomes of prostate and urothelial cancers through translational research. The long-term goal of the program is to reduce mortality for advanced prostate and urothelial cancers and improve outcomes for localized prostate and urothelial disease.
Research themes
We direct our research interests at three highly interactive research themes, including:
- Investigate mechanisms of drug resistance to current therapies — This theme builds on our extensive research into castration-resistant prostate cancer (CRPC), chemoresistance in urothelial cancer and the translation of laboratory discoveries into clinical trials. We study androgen regulation in detail, focusing on aberrant AR activation by kinases, transcription factors, cytokines, intracrine androgens, microRNAs and coregulators.
- Identify molecular targets and develop therapeutic approaches — This theme stems from our research on resistance mechanisms and deep sequencing of biopsy specimens to identify druggable genetic targets. Using a patient-derived xenograft platform, we evaluate treatment efficacy, investigate resistance and translate findings into precision cancer medicine.
- Improve outcomes for localized cancers — This theme focuses on symptom self-management, treatment decision support, sexual recovery, social support and wellness among patients living with localized genitourinary cancers.
These themes use a translational approach that integrates preclinical models and clinical applications to develop mechanism-based treatments for prostate and urothelial cancers. The goal is to overcome resistance, optimize response and minimize toxicity. The department’s research programs foster collaboration and knowledge exchange with the prostate and urothelial cancer program at UC Davis Comprehensive Cancer Center.
In addition, we have an active cancer stem cell program focused on uncovering the mechanisms and biomarkers involved in cellular development. By studying the induction of human embryonic stem cells into specialized urothelial cells, we aim to advance bladder regeneration and gain critical insights into the origins of bladder cancer.
Research Highlights and Major Discoveries
- Anti-androgen therapies: We have identified several novel resistance mechanisms including AR-V7, AKR1C3, autophagy, IL6/Stat3, and miRNAs. Efforts are devoted to targeting these mechanisms. Clinical trials are currently being developed to target AR-V7 using niclosamide, and to target AKR1C3 using indomethacin to improve enzalutamide therapy for CRPC patients, which is supported by DOD IMPACT award.
- We discovered that niclosamide, an FDA approved medicine commonly prescribed to fight parasitic worms, is a potent inhibitor of AR-V7, and can dramatically enhances the efficacy of anti-androgen drugs such as enzalutamide and abiraterone (Clin Cancer Res 2014, Oncotargets 2016). In animal models, when enzalutamide or abiraterone and niclosamide were given concurrently, AR-V7 expression was inhibited, staving off resistance to enzalutamide and abiraterone. These findings provide a warrant for investigation of niclosamide in patients with enzalutamide/abiraterone resistant CRPC. Based on these encouraging preclinical data, we have reformulate niclosamide and received IND approval for phase I/II clinical trials in CRPC patients, which are currently undergoing at UC Davis.
- We found that intracrine androgens and AKR1C3 are active in enzalutamide resistant cells in vitro and in vivo. Indomethacin can inhibit AKR1C3 activity and significantly inhibits enzalutamide resistant tumor cell growth. While indomethacin alone significantly suppressed tumor growth, the effect was further enhanced in combination with enzalutamide (Cancer Res 2015). Clinical trials to test targeting AKR1C3 pathways with indomethacin to improve enzalutamide therapy are currently under investigation at UC Davis, which is supported by DOD IMPACT award.
- We demonstrated that in mice orthotopically implanted with enzalutamide resistant cells, the combination of enzalutamide with metformin significantly reduced tumor growth when compared to the control groups. Our preclinical data have been translated into a Phase I-II trial of enzalutamide with metformin, integrated into the SU2C West Coast Dream Team award. Bone marrow biopsies of patients with an AR gene signature will be used as an integrated biomarker.
- Targeting ABCB1 to overcome resistance to docetaxel. Docetaxel is currently the first-line chemotherapy for CRPC, however, docetaxel resistance rapidly develops. Identifying the critical mechanisms giving rise to docetaxel resistance is the major challenge in advanced prostate cancer. We found that ABCB1 was upregulated in docetaxel-resistant CRPC cells. Knockdown of ABCB1 genetically or with apigenin, a natural product of the flavone family that was identified as an inhibitor of ABCB1 expression, resensitized these cells to docetaxel treatment by enhancing apoptotic cell death (Mol Can Ther 2013). We further demonstrated that enzalutamide and bicalutamide could reverse ABCB1-mediated docetaxel resistance. The combination of bicalutamide with docetaxel had a significant anti-tumor effect in both AR-positive and AR-negative docetaxel resistant xenograft models (Clin Cancer Res 2015). We are currently testing if the combination of apigenin or bicalutamide with docetaxel could improve docetaxel treatment in CRPC.